Metastatic sporadic malignant peripheral nerve sheath tumor (sMPNST) is associated with only 17% five-year survival rate using standard chemotherapy and there are no 10-year survival reports with the exception of a case report wherein a patient with metastatic sMPNST is still alive with no active disease and on no further cancer therapy, >12 years from DeltaRex-G treatment initiation. In this case report, we describe an interim alternative treatment regimen designed and used by a patient with metastatic sMPNST, while awaiting the return, GMP bioproduction, and QC certification of DeltaRex-G as a potential treatment option. We report on the successful control of metastatic tumor growth over a one-year treatment period using the Hope Protocol consisting of artemisinin, curcumin, cannabis oil, disulfiram, fenbendazole, mebendazole, albendazole, atorvastatin, doxycycline, vitamin C, vitamin E, a plant-based diet, sans refined sugar, yoga, acupuncture, meditation, exercise and hot sauna, and we discuss their biochemical mechanisms of action.
CITATION STYLE
Gordon, E., Dang, J., Angel, N. L., Brigham, D. A., Ostendorf, L., Jafari, O., … Hall, F. L. (2021). Control of Metastatic Tumor Growth in a Patient with Sporadic Metastatic Malignant Peripheral Nerve Sheath Tumor (sMPNST) Using the Hope Protocol, an Alternative Treatment Regimen for Cancer. Integrative Journal of Medical Sciences. https://doi.org/10.15342/ijms.2021.453
Mendeley helps you to discover research relevant for your work.